AVBP vs. INDV, JANX, ACAD, ARVN, BHC, MRVI, DCPH, RYTM, AGIO, and AMRX
Should you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Indivior (INDV), Janux Therapeutics (JANX), ACADIA Pharmaceuticals (ACAD), Arvinas (ARVN), Bausch Health Companies (BHC), Maravai LifeSciences (MRVI), Deciphera Pharmaceuticals (DCPH), Rhythm Pharmaceuticals (RYTM), Agios Pharmaceuticals (AGIO), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical preparations" industry.
ArriVent BioPharma (NASDAQ:AVBP) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, community ranking, risk, institutional ownership, earnings, dividends and analyst recommendations.
Indivior has higher revenue and earnings than ArriVent BioPharma.
ArriVent BioPharma received 5 more outperform votes than Indivior when rated by MarketBeat users.
Indivior has a net margin of 0.44% compared to ArriVent BioPharma's net margin of 0.00%. Indivior's return on equity of 842.72% beat ArriVent BioPharma's return on equity.
In the previous week, Indivior had 4 more articles in the media than ArriVent BioPharma. MarketBeat recorded 5 mentions for Indivior and 1 mentions for ArriVent BioPharma. Indivior's average media sentiment score of 1.39 beat ArriVent BioPharma's score of 0.93 indicating that Indivior is being referred to more favorably in the news media.
ArriVent BioPharma presently has a consensus target price of $29.25, indicating a potential upside of 50.70%. Indivior has a consensus target price of $36.00, indicating a potential upside of 96.51%. Given Indivior's higher possible upside, analysts clearly believe Indivior is more favorable than ArriVent BioPharma.
9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Indivior beats ArriVent BioPharma on 9 of the 11 factors compared between the two stocks.
Get ArriVent BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ArriVent BioPharma Competitors List
Related Companies and Tools
